Share on StockTwits

Nektar Therapeutics (NASDAQ:NKTR)‘s stock had its “buy” rating restated by research analysts at Roth Capital in a report released on Thursday.

A number of other analysts have also recently weighed in on NKTR. Analysts at Zacks reiterated an “underperform” rating on shares of Nektar Therapeutics in a research note on Monday, August 4th. They now have a $11.00 price target on the stock. Finally, analysts at Ladenburg Thalmann initiated coverage on shares of Nektar Therapeutics in a research note on Thursday, June 26th. They set a “buy” rating and a $20.00 price target on the stock. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $16.00.

Shares of Nektar Therapeutics (NASDAQ:NKTR) traded down 0.52% during mid-day trading on Thursday, hitting $13.32. 1,087,198 shares of the company’s stock traded hands. Nektar Therapeutics has a 52-week low of $8.87 and a 52-week high of $15.34. The stock has a 50-day moving average of $12.11 and a 200-day moving average of $12.34. The company’s market cap is $1.696 billion.

Nektar Therapeutics (NASDAQ:NKTR) last announced its earnings results on Thursday, July 31st. The company reported ($0.26) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.37) by $0.11. The company had revenue of $28.50 million for the quarter, compared to the consensus estimate of $19.76 million. During the same quarter last year, the company posted ($0.37) earnings per share. Nektar Therapeutics’s revenue was down 15.9% compared to the same quarter last year. On average, analysts predict that Nektar Therapeutics will post $-0.65 earnings per share for the current fiscal year.

Nektar Therapeutics is a clinical-stage biopharmaceutical company which develops a pipeline of drug candidates that utilize company platforms.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.